Publications by authors named "Binhua Lei"
Article Synopsis
- Targeted therapy using dabrafenib and trametinib is effective for NSCLC patients with the BRAF V600E mutation, but options are limited for those with other BRAF mutations.
- A case study highlights a patient with a rare BRAF N581S mutation who responded well to combined treatment with anlotinib and tislelizumab.
- The authors aim to raise awareness about the significance of non-V600 BRAF mutations in NSCLC through this unique case report.
Background: Triple-negative breast cancer (TNBC) is a special kind of breast cancer with strong ability of invasion and metastasis. UCHL1 belongs to the ubiquitin carboxy-terminal hydrolase family and is found to be increased in a variety of malignancies, but its expression in TNBC is unknown.
Methods: First, we analyzed the expression of UCHL1 in 128 TNBC specimens and paired adjacent normal tissues from 17 TNBC patients undergoing curative resection by immunohistochemistry.